PierianDx is catalyzing global adoption of genomic sequencing in healthcare
PierianDx is catalyzing global adoption of genomic sequencing in healthcare by empowering physicians in the laboratory and clinic to more effectively diagnose and treat patients with cancer and other complex diseases. PierianDx’s industry-leading genomic SaaS solutions, CAP and CLIA accredited laboratory, and shared knowledgebase are used by health systems, cancer centers and commercial laboratories worldwide driving the most integrated approach across the clinical care spectrum. From genomic sequencing and biomedical informatics in the laboratory to reporting and decision support at the patient’s bedside, PierianDx has rapidly become the trusted source of ‘wisdom’ in every advanced genomic report.
Announced Date | Round | Money Raised | Number of Investors | Lead Investors | Post Valuation | |
---|---|---|---|---|---|---|
Jan 7, 2016 | Series A | $9.25M | 2 | Health Catalyst | — | Detail |
Investor Name | Lead Investor | Funding Round |
---|---|---|
Health Catalyst | Yes | Series A |
Inova Translational Medicine Institute | — | Series A |